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SUMMARY
Pediatric osteosarcoma is characterized by multiple
somatic chromosomal lesions, including structural
variations (SVs) and copy number alterations
(CNAs). To define the landscape of somatic muta-
tions in pediatric osteosarcoma, we performed
whole-genome sequencing of DNA from 20 osteosar-
coma tumor samples and matched normal tissue in a
discovery cohort, as well as 14 samples in a valida-
tion cohort. Single-nucleotide variations (SNVs) ex-
hibited a pattern of localized hypermutation called
kataegis in 50% of the tumors. We identified p53
pathway lesions in all tumors in the discovery cohort,
nine of which were translocations in the first intron of
the TP53 gene. Beyond TP53, the RB1, ATRX, and
DLG2 genes showed recurrent somatic alterations
in 29%–53% of the tumors. These data highlight the
power of whole-genome sequencing for identifying
recurrent somatic alterations in cancer genomes
that may be missed using other methods.
INTRODUCTION
Osteosarcoma is the most common malignant bone tumor in
children and adolescents, with approximately 400 new cases
each year in the United States (Ottaviani and Jaffe, 2009).
Although most cases are sporadic, the risk of osteosarcoma is
increased in patients with various genetic diseases, including
hereditary retinoblastoma, Li Fraumeni syndrome, and germline
mutations of RecQL4 (Hicks et al., 2007; Kleinerman et al., 2005;
McIntyre et al., 1994). Current multimodal therapies that
incorporate surgical excision and combination chemotherapy
(i.e., doxorubicin, methotrexate, and cisplatin) cure approxi-
mately 70% of patients (Meyers et al., 2005). However, clinical
outcomes and therapeutic strategies have remained virtually
unchanged over the past 20 years (Smith et al., 2010).
In this study, we characterized the genomic landscape of
osteosarcoma by performing whole-genome sequencing (WGS)
on34osteosarcomatumorandmatchednontumor tissuesamples
from 32 patients. Our results demonstrate that pediatric osteosar-
comas haveone of the highest rates of SVs of any pediatric cancer
sequenced to date (Downing et al., 2012), but relatively few recur-
rent single-nucleotide variations (SNVs). However, when SVs and
SNVs were combined, inactivating mutations were identified in
several cancer pathways. Taken together, our results provide in-
sights into the molecular pathology of pediatric osteosarcoma
and demonstrate that comprehensive WGS is required to eluci-
date the complete genetic landscape of osteosarcoma.
RESULTS
WGS of Primary and Metastatic Osteosarcomas
Using a paired-end sequencing approach, we generated 10,265
Gb of sequence data for DNA in 20 osteosarcomas andmatched
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Figure 1. WGS of Osteosarcoma
(A) Representative CIRCOS plots of validated mutations and chromosomal lesions in diagnostic and metastatic osteosarcoma tumors from different patients.
LOH (orange), gain (red), and loss (blue) are shown. Intrachromosomal (green lines) and interchromosomal (purple lines) translocations are indicated. Sequence
mutations in RefSeq genes included silent SNVs (green), nonsense and missense SNVs (brown), splice-site mutations (dark blue), and insertion/deletion
mutations (red). An additional track was added to the innermost ring of the plot showing the density of SNVs to highlight regions adjacent to SVs characteristic of
kataegis.
(legend continued on next page)
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normal DNA from 19 osteosarcoma patients in a discovery
cohort, and 14 tumor specimens and matched normal DNA
from 13 patients in a validation cohort (Table S1); 9,671 Gb
(94%) were successfully mapped to the reference genome
(Table S2). In the discovery cohort, the samples included 17 pre-
treatment diagnostic samples (16 primary and one metastatic),
one recurrent metastatic sample (SJOS001), and two tumor
specimens (SJOS010_D and SJOS010_M) from the same
patient with metachronous osteosarcoma (Table S1).
The average genome coveragewas 443 and the average exon
coverage was 393; 99% of SNPs detected across all 39
genomes showed concordance with their corresponding SNP
array genotype calls (Table S2). Validation was carried out using
custom liquid capture for all SNVs, SVs, and insertions or dele-
tions (indels) identified in the original sequence data. Combining
the discovery and validation cohorts, we identified 50,426
validated somatic sequence mutations and 10,806 SVs
(Table S3). These included 856 nonsilent tier 1 mutations in
genes, 4,651 tier 2 mutations in evolutionarily conserved regions
of the genome, and 43,782 tier 3 mutations in nonrepetitive
regions of the genome that are not part of tier 1 or tier 2
(Table S3). The average number of sequence mutations was
1,483.1 per case (range 610–5,178), with 25.2 mutations per
case (range 5–103) resulting in amino acid changes (Table S3).
The estimated mean mutation rate was 1.15 3 106 per base
(range 4.90 3 107–3.99 3 106). Among the validated SVs,
377 were predicted to produce an in-frame fusion protein
(Table S3). Good-quality RNA sequencing (RNA-seq) data were
available for five tumors with 64 predicted fusion SVs. Among
them, 15 SVs (23%) were expressed (Table S3).
Primary and metastatic osteosarcomas had high rates of
validated SVs (Figures 1A and S1). The number of SVs and
CNVs, background mutation rate, and number of nonsilent tier
1mutations were significantly higher in osteosarcoma compared
with medulloblastoma and T-ALL (Robinson et al., 2012; Zhang
et al., 2012; Figure 1B). However, only the number of SVs was
significantly higher in osteosarcoma compared with another
pediatric solid tumor with high rates of somatic alterations
(embryonal rhabdomyosarcoma) (Chen et al., 2013; Figure 1B).
The global patterns revealed by the WGS analysis of osteosar-
coma suggest that themajority of SVs and CNVswere generated
by sequential accumulation of SVs (Figures 1C and 1D), but
chromothripsis (Stephens et al., 2011) was detected at specific
genomic regions in four samples (chr14 in SJOS002_D, chr17q
in SJOS003_D, chr6q in SJOS005_D, and chr13 in SJOS010_M;
Supplemental Experimental Procedures). We used a modified
version of GISTIC analysis to identify regions of the osteosar-
coma genome with recurrent copy number alterations in the
discovery cohort. The TP53, RB1, MYC, and PTEN pathways,
as well as ATRX, LSAMP-AS3, CCNE1, and a genomic region
on chromosome 16 containing COPS3, PMP22, MAPK7,
NCOR1, and UBB, were recurrently mutated (Figure S1C).
Among SNVs with sufficient coverage in both SJOS010 samples
(203), we validated 673 SNVs in both samples, 1,686 in
diagnostic-only samples, and 1,408 in metastasis-only samples,
indicating that these two tumors shared a limited amount of com-
mon mutations and were divergent early in the progression.
Applying the GRIN method (Pounds et al., 2013) on functional
mutations (including SNVs and indels) and SVs, we identified
TP53 (false discovery rate [FDR] = 3.6E-51, mutated in 28/34
samples) RB1 (FDR = 1.1E-5, mutated in 10/34 samples),
ATRX (FDR = 2.4E-4, mutated in 10/34 samples), and DLG2
(FDR = 0.044, mutated in 18/34 samples) as significantly
mutated genes. All genes except DLG2 were mutated by point
mutations (nine for TP53, three for RB1, and five for ATRX) and
SVs in multiple tumors (18 for TP53, seven for RB1, and five for
ATRX). DLG2 was exclusively mutated by SVs.
Osteosarcoma Tumor Purity and Tumor Heterogeneity
Using the purity-adjusted mutant allele fraction (MAF)
derived from deep sequencing of all SNVs by capture enrich-
ment and Illumina sequencing, we analyzed intratumor hetero-
geneity. Eleven tumors (SJOS001_M, SJOS004, SJOS005,
SJOS008, SJOS012, SJOS013, SJOS015, SJOS001103_D1,
SJOS001105_D1, and SJOS001123_D1, and SJOS001125_D1)
were excluded from quantitative heterogeneity analysis due to
an insufficient number of SNVs in copy-neutral regions.
Statistical modeling demonstrated that 61% (14/23) of osteosar-
comas in this group had evidence of multiple clones, includ-
ing metastatic samples SJOS010_M, SJOS001107_M1 and
SJOS001107_M2 (Figure S2).
Kataegis in Osteosarcoma
To determine whether there was any relationship between the
SVs and location, distribution, or type of SNV in the osteosar-
coma genomes, we plotted the validated SVs and SNVs for
each sample andanalyzed the intermutationdistance (FigureS2).
Hypermutable regions with the five hallmarks of kataegis (Nik-
Zainal et al., 2012) were identified in 17 of the osteosarcoma
tumors (Figure 2A). These five hallmarks of kataegis are (1)
enriched C->T and C->G substitutions at TpCpX trinucleotides
(Figures 2B and 2C), (2) the same class of nucleotide mutation
occurring for contiguous stretches before switching to a different
class (Figure 2D), (3) mutations within short stretches of the
genome occurring on the same parental chromosome (Fig-
ure S2), (4) clustering of heavily mutated short stretches of the
genome at multiple scales (Figure 2E), and (5) association of
the hypermutated region with SV breakpoints (Figure 2E). The
regions of the genome with kataegis were not recurrent in our
cohort and were not associated with recurrently mutated genes
(B) Boxplots of validated basal mutation rate (BMR) and numbers of nonsilent SNVs, total SVs, and total CNVs in embryonal rhabdomyosarcoma (ERMS) and
alveolar rhabdomyosarcoma (ARMS) tumors in the discovery cohort. * represents statistical significance of p < 0.001 as compared with the osteosarcoma
genomes.
(C) Representative plot of sequence reads on chromosome 12 for the matched germline (green) and tumor (red) sample. Several distinct regions of copy number
change are identified (arrows) spanning the MDM2 gene consistent with sequential chromosomal lesions.
(D) MDM2 FISH of SJOSO18 showing amplification (red) relative to the probe for chromosome 12 (green). T-ALL, T cell acute lymphoblastic leukemia; MB,
medulloblastoma.
See also Figures S1–S3 and Tables S1–S3.
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Figure 2. Kataegis in Osteosarcoma
(A) Rainfall plot showing the Log10 of the intermutation distance versus genomic position for a representative osteosarcoma sample (SJOS005) with evidence of
kataegis. The chromosomes are demarcated by gray shading and the number of SVs in each chromosome is shown in brown at the bottom. The validated SNVs
are plotted and color-coded by the type of mutation.
(legend continued on next page)
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in osteosarcoma (Figure S2). Tier 1 SNVs in kataegis regions
were not significantly associated with the expression status
(p = 0.16 by Fisher’s exact test).
Chronology of Kataegis, SVs, and Aneuploidy in
SJOS005
SJOS005 had the highest proportion (11%) of kataegis SNVs
in our cohort. The large number of kataegis SNVs (n = 212)
coupled with the accurate measurement of the MAFs of all
SNVs derived from deep sequencing allowed us to analyze
the chronology of kataegis in relation to other mutational
events in this tumor. First, we examined MAFs of SNVs in
kataegis microclusters containing five or more consecutive
kataegis SNVs within 10 kb. The MAF variance was relatively
small (6.7% of overall variance) within a microcluster, although
there was a wide range of MAFs across microclusters (range
0.142–0.839, median 0.364; Figure S2). This pattern, along
with the observation that SNVs in a microcluster occurred on
the same parental chromosome, supports the hypothesis
that SNVs in a kataegis microcluster originated from a single
event. MAF analysis of SVs flanking ‘‘kataegis’’ clusters (range
0.132–0.866, median 0.396) also showed a significant positive
correlation (p = 4.56E-5) with those of ‘‘kataegis’’ SNVs,
and there was no significant difference between them (p =
0.143 by Wilcoxon signed rank test), indicating that the neigh-
boring SVs likely arise simultaneously with kataegis SNVs
(Figure S2).
(B) The proportion of each type of validated SNV in osteosarcomas with evidence of kataegis versus those without kataegis.
(C) The distribution of each nucleotide sequence 50 to the C mutations in tumors with kataegis and those without kataegis.
(D) A rainfall plot in a representative regions of chromosome 3 in SJOS005 with kataegis showing the strand of the hypermutation based on the C>T or G>A
sequence clusters.
(E) A macrocluster of hypermutation with evidence of kataegis on chromosome 3 of SJOS005, with two sequential magnifications (boxes) showing the existence
of microclusters within a single macrocluster.
See also Figure S2.












































Figure 3. Validated Mutations in TP53
(A) Structure of the TP53 gene showing the trans-
activation, proline, DNA binding, and oligomeriza-
tion domains with splice-site, frameshift, and
missense mutations in tumors of the 19 patients in
the discovery cohort.
(B) Structure of the genomic locus of the TP53 gene
showing the exon boundaries color-coded in
accordance with the protein domains shown in (A).
Sites of interchromosomal translocations are
indicated by black arrowheads between exons 9
and 10. The sizes of the introns and exons are
scaled proportionally except for intron 1, which is
much larger than the other introns in human TP53.
(C) A magnified view of intron 1 of TP53 showing the
deletions (blue arrowheads), intrachromosomal
translocations (red arrowheads), and interchromo-
somal translocations (black arrowheads).
See also Figure S3 and Table S4.
SJOS005, like most osteosarcomas, ex-
hibits aneuploidy with copy number gains
spanning more than 50% of the genome.
Kataegis SNVs were significantly enriched
in regions of the genomewith four or more copies comparedwith
nonkataegis SNVs (p < 2.2e-16 by Fisher’s exact test; Figure S2).
However, the MAF distribution of kataegis SNVs showed a large
fraction of SNVs with multiple copies of the mutant allele in
amplified regions, whereas only a single copy of mutant alleles
was found in the majority of the nonkataegis SNVs (Figure S2).
Taken together, these data suggest that kataegis likely occurs
before global aneuploidy, and nonkataegis SNVs occur primarily
after the aneuploidy.
SVs in TP53
The p53 pathway was mutated in all 20 tumor samples from
the 19 patients in our discovery cohort. The majority (95%,
19/20) had either sequence mutations or SVs in the TP53
gene, and one (SJOS018) had an MDM2 amplification (see Fig-
ures 1C and 1D; Table S3). Surprisingly, 55% of the tumors
(11/20) had SVs in the TP53 gene, and the majority of those
were translocations with breakpoints that were confined to
the first intron of the gene (90%, 19/21 SV breakpoints; Figures
3A–3C; Table S4). Indeed, some tumors had rearrangements in
both alleles of TP53, resulting from two or more independent
translocations (Table S4). One patient’s tumor (SJOS006) had
a germline SNV (R337H), one (SJOS012) had a somatic
splice-site mutation, and two (SJOS004 and SJOS010) had
somatic missense SNVs (Figures 3A–3C; Table S4). The
remaining four patients had tumors that harbored indels in
the TP53 gene. Loss of heterozygosity (LOH) at the TP53 locus
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was evident in 40% (8/20) of the osteosarcoma tumors. In
total, 15 tumors had biallelic inactivation of TP53, four had
monoallelic inactivation of TP53, and one had MDM2 amplifi-
cation (Figure 1C; Table S4).
To further validate the translocations in the TP53 gene identi-
fied by WGS, we developed a break-apart fluorescence in situ
hybridization (FISH) assay with separate probes spanning the
50 and 30 regions of the gene (Figure 4A). We also developed a
FISH assay with a probe spanning the entire TP53 gene
(Figure 4A) to assess ploidy and determine whether the gene
was deleted. To complement the FISH analysis, we performed
p53 immunostaining to verify that the tumors with missense
mutations had accumulated high levels of nuclear p53 protein.
We successfully performed FISH in 18 of 20 tumors and p53
immunostaining on all 20 tumors (Table S4). Overall, there was
perfect concordance between the WGS data and the FISH
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Figure 4. FISH and Immunohistochemistry
for TP53 in Osteosarcoma
(A) Genomic location of the 50 (green) and 30 (red)
break-apart FISH probes showing their position
relative to the TP53 gene. The full-length probe used
to identify deletions at the TP53 locus is shown
in black.
(B–D) Images of hematoxylin and eosin (H&E), TP53
immunohistochemistry (IHC), and break-apart FISH
for SJOS001 with biallelic rearrangement of the
TP53 gene.
(E–G) Images of H&E, TP53 IHC, and break-apart
FISH for SJOS002 with monoallelic rearrangement
of the TP53 gene.
(H–J) Images of H&E, TP53 IHC, and break-apart
FISH for SJOS010 with polysomy and a missense
mutation leading to elevated accumulation of
nuclear TP53 protein.
(K–M) Images of H&E, TP53 IHC, and FISH using the
full-length probe (green) for SJOS008 with mono-
allelic deletion of TP53.
See also Table S5.
In an additional cohort of patient tumor
samples, we found that 50% (16/32)
had TP53 rearrangements, 22% (7/32)
had missense mutations, 16% (5/32) had
nonsense mutations, 6% (2/32) had a
TP53 deletion, and 3% (1/32) had an
MDM2 amplification (Table S5). Three
patients with tumor showed no evidence
of a p53 pathway mutation.
We did not find any significant difference
in CNV (p = 0.20 by Wilcoxon rank sum
test), SV (p = 0.85), SNV (p = 0.43), nonsi-
lent tier 1 mutations (p = 0.66), or back-
ground mutation rate (p = 0.43) in the
osteosarcoma samples with mutant p53
versus those with inactivating (nonsense,
deletion and truncation) mutations in
TP53. Survival analysis, including event-
free survival and overall survival, did not
show a significant difference in outcome for the patients whose
tumors carried TP53-missense mutations (ten patients) versus
those with TP53-truncating mutations (34 patients), with log
rank test p values of 0.88 and 0.64, respectively.
RB1, ATRX, and DLG2 Are Recurrently Mutated in
Osteosarcoma
ATRX is part of a multiprotein complex that regulates chromatin
remodeling, nucleosome assembly, and telomere maintenance.
It was recently shown that ATRXmutations in neuroblastoma are
associated with age at diagnosis (Cheung et al., 2012). Most
neuroblastomas with ATRXmutations show evidence of alterna-
tive lengthening of telomeres (ALT), as measured by WGS, telo-
mere FISH, and telomere quantitative PCR (qPCR) (Cheung
et al., 2012). In our osteosarcoma discovery cohort, we identified
five tumors (SJOS001, SJOS002, SJOS007, SJOS001112-M2,
and SJOS001117-D1) with point mutations in ATRX, and five
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Figure 5. ATRX Mutations Correlate with ALT in Osteosarcoma
(A) Diagram of the five SNVs, four deletions, and one interchromosomal SV found in the ATRX genes of the osteosarcoma cohort. Three of the samples with ATRX
SVs (SJOS006, SJOS018, and SJOS011) had matching RNA-seq data. SJ006 has a short deletion at exon 23 and the RNA-seq data confirmed a readthrough
(legend continued on next page)
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with focal deletions or SVs affecting the coding region of the
gene (Figure 5A; Table S6). There was no significant gender
bias in ATRX mutations (p = 0.25 by Fisher’s exact test) even
though it is located on the X chromosome. By immunohisto-
chemistry, 31% (6/19) of the tumors in the discovery cohort
were ATRX negative (Figure 5B; Table S6). The sample with a
missense mutation (SJOS007-R1803C) and one with an SV
(SJOS018) were heterogeneous for ATRX protein expression.
Analysis of telomere sequence reads from the WGS data
and qPCR of telomeres showed that the majority of osteosar-
comas had longer telomeres (Figures 5C and 5D), and ALT
was found in 85% (12/14) of the samples using telomere FISH
(Table S6).
Beyond TP53 and ATRX, there were significant recurrent
mutations in RB1 (10/34, FDR q = 1.1E-5) and DLG2 (18/34,
FDR q = 0.044). DLG2 encodes a multi-PDZ domain protein
that is involved in epithelial polarity during cell division and has
been implicated in cancer cell invasion. In Drosophila, DLG is a
tumor suppressor, but a clear tumor-suppressor function has
not yet been confirmed for DLG2 in human cancer.
SVs in Cancer Genes
SVs contributed 91% (9,605/10,523) of all functional genetic
lesions in our osteosarcoma cohort. In total, 122 cancer genes
had at least one SV breakpoint (Table S7) and all but one tumor
(SJOS001118_D1) had at least one breakpoint (range 1–40) in a
cancer gene. SV breakpoint enrichment in the cancer genes
was highly significant even when we excluded TP53 from the
list (p = 2.5E-6). Twelve of the 34 tumors (35%) achieved signif-
icant enrichment of SV breakpoints in cancer genes individually.
In addition, some tumors have ‘‘fold-back intrachromosomal
translocations’’ (Campbell et al., 2010) to inactivate tumor-
suppressor genes (Figure S3). These results further support the
hypothesis that genomic instability leads to lesions in various
cancer genes.
DISCUSSION
WGS of osteosarcoma demonstrated that the rate of SNVs
was similar to that in other pediatric solid tumors, and only a
few recurrent SNVs were detected. Approximately half of the
osteosarcomas in our discovery cohort had a pattern of hyper-
mutation associated with SVs, called kataegis (Nik-Zainal
et al., 2012). The regions of the genome with kataegis were
not recurrent, and none of the most recurrently mutated genes
were found in regions of kataegis. Chromosomal lesions,
rather than SNVs, were the major mechanism of recurrent
mutations, and many of the most significant chromosomal
lesions were found in known cancer genes, including TP53,
RB1, and ATRX.
Genomic Stability and Osteosarcoma Initiation and
Progression
The most frequent mutation in osteosarcoma is in TP53. By our
estimates, both alleles aremutated in asmany as 80%of tumors,
and at least one allele was mutated in >90% of tumors. These
data suggest that p53 mutations are a major oncogenic driver
in osteosarcoma. Although this finding is not novel, what is
surprising is the mechanism of inactivation. Most TP53 muta-
tions are SVs in intron 1, which suggests that either the TP53
locus is particularly susceptible to SVs or SVs occur at a high
rate in the osteosarcoma tumor-initiating cell. Aside from osteo-
sarcomas and prostate cancers (Baca et al., 2013; Berger et al.,
2011), there is no evidence of TP53 SVs in any other cancer, so
the locus is probably not uniquely susceptible to chromosomal
rearrangements. These data raise an intriguing possibility:
genomic instability characterized by high rates of CNVs and
SVs may precede TP53 inactivation, and may be the underlying
mechanism that initiates and promotes osteosarcoma.
Kataegis in Osteosarcoma
In a recent WGS study, Nik-Zainal et al. (2012) described a
distinct hypermutation phenomenon in breast cancer that they
termed kataegis. Here, we found SNV clusters with the same
five characteristics of kataegis in 50% of the osteosarcomas
analyzed by WGS. Interestingly, genomic regions encoding
TP53 and ATRX, the two most frequently mutated genes in oste-
osarcoma, did not exhibit this pattern of local hypermutation.
Furthermore, there was no association between kataegis and
TP53 mutation type (i.e., SNV, indel, or SV).
TP53-Mutant or -Null Osteosarcomas
Previous studies have estimated that 20%–70% of osteosar-
comas carry mutations in the p53 pathway (Lonardo et al.,
1997; Wunder et al., 2005), but our data suggest that the propor-
tion is much higher. For example, Wunder et al. (2005)
sequenced exons 4–10 of the TP53 gene in 196 osteosarcoma
samples and found that 19.4% (38/196) had TP53 SNVs. The
investigators concluded that the remaining 80.6% (158/196)
had wild-type TP53 (Wunder et al., 2005). They went on to
show that event-free survival was indistinguishable between
the two groups (wild-type and mutant TP53) (Wunder et al.,
2005). SVs in the first intron of TP53 were not analyzed in that
study, even though such lesions had previously been reported
in osteosarcoma (Miller et al., 1990). Our data suggest that the
majority of the tumors identified as TP53 wild-type in the study
event that would result in a T1885 frameshift. For SJOS011, the RNA-seq andWGS data supported a junction connecting exon 1 to exon 28, creating a nonsense
mutation (M6R*). For SJOS018, the RNA-seq and WGS data supported a deletion connecting exon 1 to exon 13, thereby creating an in-frame fusion protein
(M6RS1406). The WGS for SJOS016 predicts a deletion that connects exon 1 to exon 16, producing a frameshift (M6fs).
(B) Representative IHC for ATRX showing nuclear ATRX in a sample with intense staining and wild-type ATRX (SJOS012), a sample with fainter nuclear localized
ATRX (SJOS014), and a sample with a nonsense mutation (SJOS001). Arrows indicate representative nuclei stained positive for ATRX. Asterisks indicate ATRX
immunopositive vascular endothelial cells among the tumor cells that are negative for ATRX IHC.
(C and D) Relative telomere length in the osteosarcomas compared with that in the matched germline DNA, as analyzed by WGS and qPCR.
(E) Representative telomere FISH showing characteristics of ALT (arrow) in an osteosarcoma with an ATRX deletion.
See also Tables S6 and S7.
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by Wunder et al. (2005) actually had inactivating SVs in TP53.
Therefore, it may be useful to revisit the association of TP53
pathway inactivation with osteosarcoma outcome in a large
cohort of patient samples.
EXPERIMENTAL PROCEDURES
Full details regarding sample acquisition, molecular and biochemical proce-
dures, informatics, and WGS are provided in the Supplemental Information.
All tumors in this study were obtained from St. Jude Children’s Research
Hospital (SJCRH) patients. The SJCRH IRB approved experiments involving
human subjects and informed consent was obtained from all subjects.
ACCESSION NUMBERS
The European Bioinformatics Institute accession number for the sequencing
data reported in this paper is EGAS00001000263.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and seven tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.03.003.
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Figure S1 related to Figure 1. Copy number analysis of osteosarcoma discovery 
cohort. A) Copy number analysis for all 34 osteosarcomas in the discovery cohort with 
red indicating gain and blue indicating loss. B) Histogram of the type of mutations (SNV, 
CNV, SV, indel) across the osteosarcoma tumors in the discovery cohort. C) GISTIC 
analysis of the copy number changes in the osteosarcoma discovery cohort with green 
indicating gains and red indicating loss. The dashed lines represent cutoff for statistical 
significance and the individual chromosomes are labeled along the bottom of the plot. D) 
CIRCOS plots of all 34 tumors sequenced by WGS in this study. 
 
Table S1 related to Figure 1. Clinical features of discovery and validation cohorts. 
Provided as a separate file. 
 
Table S2 related to Figure 1. Sequence coverage data. 
Provided as a separate file. 
 
Table S3 related to Figure 1. Validated mutations. 
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Figure S2 related to Figure 2. Analysis of tumor heterogeneity  and kataegis. A) 
Tumor purity adjusted mutant allele fraction (MAF) for samples analyzed by whole
genome sequencing. The actual tumor purity that was used to adjust the MAF is shown as 
a percentage for each tumor. The number of qualifying SNVs (n) used to plot the density 
plot is shown for each tumor. B) Screenshot of WGS data with individual sequence reads 
showing kataegis hypermutation on the same DNA strand. C) Genomewide distribution of 
mutation hotspots in osteosarcoma shown as the ratio between observed mutation rate in 
the window over the genomewide mutation rate within a 3.2 Mb window across the 
genome for the 34 samples analyzed by WGS. D) Kataegis SNVs showed different MAFs 
among different microclusters although SNVs within a microcluster shared similar 
MAFs. E) Comparison of MAFs of SVs and SNVs in kataegis regions. F) The distribution  
of intermutation distance and distance from a SNV to nearest SV breakpoint in SJOS005, 
showing majority of mutations in the genome have a intermutation distance around 1 Mb 
while a small portion of SNVs have an intermutation distance smaller than 10 kb. G) 
Distribution of copy number variation and SNV intermutation distance (log10) which 
shows higher proportion of closely spaced SNVs (i.e. kategis SNVs)  occur in amplified 
regions.   H )  Distribution of mutant allele fraction of non-kataegis SNVs (left panel) and 
kataegis SNVs (right panel) in regions of different copy number state in SJOS005. SNVs 
acquired before amplification show multiple mutant allele fraction (MAF) peaks, 
depending on whether the mutant allele or the reference allele is amplified while 
mutations acquired after amplification showed a single MAF corresponding to mutation 












Figure S3 related to Figure 3. TP53 translocations in osteosarcoma.  A) Diagram of 
the predicted fusion gene generated by the interchromosomal translocation between the 
TP53 gene and the SFSWAP gene in SJOS007_D. B) Diagram of the fold-back 
translocation in the TP53 gene in SJOS001_M (upper panel).  Diagram of the fold-back 
translocation in the RB1  gene in SJOS015_D (lower panel). The translocations are 
indicated by the red arrows. 
 
Table S4 related to Figure 3. Analysis of p53 mutations in osteosarcoma. 
Provided as a separate file. 
Table S5 related to Figure 4. Analysis of p53 analysis and clinical features. 
Provided as a separate file. 
Table S6 related to Figure 5. ATRX analysis in osteosarcoma. 
Provided as a separate file. 
Table S7 related to Figure 5. Cancer gene mutations in osteosarcoma. 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
	  
Tumor Samples 
Twenty high-grade intermedullary osteosarcoma samples with matched normal tissue 
from 19 patients were subjected to the whole genome sequence (WGS) analysis. The 
samples included 16 untreated primary and 4 metastatic tumors, the latter obtained from 3 
patients, of whom two had metastatic disease at presentation and one had tumor 
recurrences. The tumors occurred in 11 males and 8 females ranging in age from 8-22 
years of age (median age, 14 years). H&E slides of the tumors were retrieved from the 
Pathology Archives at St. Jude Children’s Research Hospital for review and the tumors 
were classified in the following histologic subtypes: osteoblastic (10 tumors), mixed 
pattern (3 tumors), telangiectatic (3 tumors), fibroblastic (2 tumor), chondroblastic (1 
tumor), and small cell (1 tumor). Clinical features of the validation cohort are provided in 
Suppl. Table 1. For the p53 analysis cohort, 38 samples from 31 additional patients were 
analyzed for alterations in the p53 pathway. The clinicopathologic data and the results of 
the molecular genetic assays on validation cohort are provided in Supplemental Table 4. 
 
TP53 Immunostaining 
 The corresponding formalin-fixed, paraffin-embedded (FFPE) tissue blocks for each 
specimen were cut at 4 micron thickness. Immunohistochemical staining was performed 
using an antibody directed against p53 protein (DO-7, DAKO, 1:50) and processed with 
standard heat-induced epitope retrieval (Ventana CC1) and the Ventana IVIEW detection 
systems. p53 nuclear staining was scored using a previously published scoring 
system(Papai et al., 1997) with a minor modification as follows: samples with no staining 
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cells were scored as negative; samples with <5% p53 immunopositive cells were scored 
as rare; samples with  5-25% immunopositive cells were scored as 1+; samples with 26-
50% immunopositive cells were scored as 2+; samples with >50% immunopositive cells 
were scored as 3+.    
 
TP53 and MDM2 Fluorescence In Situ Hybridization Studies  
The fluorescence in situ hybridization (FISH) probe sets were designed using bacterial 
artificial chromosome (BAC) clones according to the UCSC Genome Bioinformatics 
database (http://genome.ucsc.edu). The TP53 dual-color break-apart FISH assay was 
developed by using RP11-1081A10 BAC clone, flanking the 3′ end of the gene– labeled 
with Rhodamine (red fluorochrome)– and the RP11-709J3 BAC clone, flanking the 5′ 
end of the gene– labeled with AlexaFluor-488 (green fluorochrome).  In addition, a TP53 
FISH probe mixture was constructed to enumerate the gene copy using the RP11-89D11 
BAC clone, spanning the entire sequence of TP53 that was labeled with green 
fluorochrome and the control RP11-64J19 that was labeled with red fluorochrome. FISH 
for MDM2 was set up using the RP11-611O2 BAC clone spanning the entire gene (red 
fluorechrome) and a probe targeting ATF1 at 12q13.1 as the control probe (green 
fluorochrome. DNA was isolated from BAC clones (BACPAC Resources, Oakland, CA) 
according to a modified Qiagen (Valencia, CA) extraction protocol. The probes were 
labeled by nick translation using a modification of the manufacturer’s protocol (Life 
Technologies, Inc., Carlsbad, CA). FISH analysis was performed on 4 micron-thick FFPE 
tissue sections using the previously published methods(Bahrami et al., 2012).  
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Hybridization signals were evaluated in 200 interphase nuclei of each sample. FISH 
images were captured and processed as previously described(Bahrami et al., 2012).  
Telomeres were analyzed in the discovery cohort using 3 different methods. The 
whole genome sequencing (WGS) data was analyzed for telomere length (described 
below) for all 20 tumors and matched normal tissue in the discovery cohort.  Quantitative 
PCR (described below) was performed to validate the results from WGS analysis for all 
10 tumors in the discovery cohort with ATRX mutations and an additional 4 samples with 
wild type ATRX to serve as controls. Matched normal DNA was used as internal control 
for each patient’s sample. Telomere FISH (see below) was performed on all tissue 
samples in the discovery cohort that had available FFPE material (non-decalcified tumor 
tissue).  All of the samples that were analyzed by telomere FISH were also analyzed for 
ATRX protein expression by immunohistochemistry (described below).  
 
Whole-Genome Sequencing, RNA-Seq and Exome Seq 
 Using a paired-end sequencing approach, we sequenced DNA from 20 tumors and their 
matching germline control DNA with an average of 30× haploid coverage per genome. 
Single nucleotide variations (SNVs) and insertions/deletions (indels) were identified 
independently algorithms by Washington University Genome Sequencing Center 
(WUGSC) and St. Jude Children’s Research Hospital (SJCRH) using different 
approaches. The results generated were then compared and a final candidate SNV and 
indel list was developed for experimental validation. 
At WUGSC, SNVs were found by Somatic Sniper that defines high quality 
somatic predictions as those sites with a somatic score greater than 40 and an average 
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mapping quality greater than 40. The predicted SNVs are compared to the most current 
version of dbSNP(Sherry et al., 2001) (build 129-130). For SNVs, we require both 
positional and allele match. In addition we also compared the predicted SNVs to SNPs 
found in CEU and YRI trios as described(Ding et al.). All predicted SNVs were filtered 
through a SNV false-positive filter developed at the Genome Institute that is based on a 
standard set of criteria including mapping quality score, average supporting read length, 
average position of the variant in the read, strand bias and the presence of homopolymer. 
Indels were called using modified SAMtools(Li et al., 2009) indel-calling algorithm as 
described(Ding et al.), Pindel(Ye et al., 2009) and GATK(Zerbino and Birney, 2008).  
At SJCRH, putative sequence variants including SNVs and indels were initially 
detected by running the variation detection module of Bambino(Edmonson et al.) using 
the following three parameters: (1) a high quality threshold for pooled tumor and 
matching normal bam files (min-quality=20, min-flanking-quality=20, min-alt-allele-
count=3, min-minor-frequency=0, broad-min-quality=10, mmf-max-hq-mismatches=4, 
mmf-min-quality=15, mmf-max-any-mismatches=6; (2) a low quality threshold for 
pooled tumor and matching normal bam files (min-quality=10, min-flanking-quality=10, 
min-alt-allele-count=2, min-minor-frequency=0, broad-min-quality=10); and (3) a high 
tolerance for the number of mismatches for normal bam file alone (min-quality=20, min-
flanking-quality=15, min-alt-allele-count=2, min-minor-frequency=0, mmf-max-hq-
mismatches=15, mmf-min-quality=15, mmf-max-any-mismatches=20). In addition to 
Bambino, putative indels were also found by a de novo assembly process which construct 
contigs using unmapped reads and re-map them to the reference genome followed by a 
Smith-Waterman alignment to detect indels. In this process, unmapped reads include (1) 
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unmapped reads whose mate are mapped to the genome; (2) reads with indels in CIGAR 
(Compact Idiosyncratic Gapped Alignment Report) string; (3) reads with at least 4 high-
quality (quality value >=20) mismatches; and (4) reads with high-quality (quality value at 
least 20) soft-clipped bases in the CIGAR string. All putative sequence variants were 
further assessed to determine their accuracy and somatic original using the processes 
described below. Velvet(Zerbino and Birney, 2008), BLAT(Kent, 2002) and SIM(Huang 
et al., 1990) were the three programs used for assembly, mapping, and Smith-Waterman 
alignment, respectively.  
A putative somatic sequence mutation determined by SJCRH process was 
collected based on the following criteria: (1) the variant site is absent in the normal-only 
analysis; (2) Fisher’s exact test P value indicates that the number of reads harboring non-
reference allele is significantly higher in tumor; (3) the non-reference allele frequency in 
normal is <=5%; and (4) mutant alleles present in both orientations. Higher P value and 
absence of non-reference allele in normal is required for a variant to be considered 
somatic if it matches dbSNP build 130 or is located in an unmappable region (determined 
by recurrence of 75mers across the reference genome) or is inside a polynucleotide 
repeat. Substitution variants are classified into four categories based on combination of 
their P value and sequence quality scores: High quality, high P value; high quality, low P 
value; low quality, high P value; low quality, low P value. P value refers to the P value 
of Fisher’s exact test comparing the distribution of the alternative allele in tumor and 
normal. High P value, P<0.05; low P value, 0.05<P<0.10. A final review process re-
maps and re-aligns the reads harboring the non-reference allele to the reference genome 
to filter potential false positive calls introduced by mapping in repetitive regions and 
alignment artifacts. For putative somatic indels, the review process re-aligns all reads in 
tumor and normal at the indel site to a mutant allele template sequence constructed by 
substituting the wild-type allele with the indel. Presence of reads in normal that cover the 
mutant allele is considered a germline variant. Structural variations including the 5 
deletions in ATRX were detected using the CREST algorithm (Wang et al., 2011) and 
CONSERTING algorithm. The data have been deposited in EBI with accession number: 
EGAS00001000263. 
Paired-end reads from mRNA-seq were aligned to the following 4 database files 
using BWA (0.5.5) aligner (4): (i) human NCBI Build 37 reference sequence, (ii) RefSeq, 
(iii) a sequence file that represents all possible combinations of non-sequential pairs in 
RefSeq exons, and (iv) AceView flat file downloaded from UCSC and representing 
transcripts constructed from human EST. The final BAM file was constructed by 
selecting the best alignment in the four databases. SV detection was carried out using 
CREST (1) and deFuse (5) as well as a novel algorithm that searched for the predicted 
junction breakpoints from detected SVs in matching WGS samples. 
For exome sequencing, OS DNA libraries were prepared from 1 ug of WGA 
material from matched samples using the Illumnia TruSeq DNA library prep kit 
Agilent Bioanalyzer to inspect quality of each library construction.  Germline and 
diagnostic library samples were independently pooled and applied for exome capture 
using the Illumina TruSeq Exome Enrichment kit as described by the manufacturer.  
Captured libraries were then clustered on the Illumina c-bot and were sequenced on an 
30
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Illumina HiSeq 2000 platform with 100 base pair end multiplexed reads at an equivalent 
of 3 samples per lane. 
We used cghMCR (an R implementation of a modified version of GISTIC 
analysis(Aguirre et al., 2004)) to find common regions of copy number alterations. To 
identify genes of significant DNA copy number alterations, we defined the genes with 
Segments Of Gain Or Loss (SGOL) scores above the 3 standard deviations of the mean 
SGOL  scores of all ‘gains’ scores as significantly amplified genes. The genes with 
SGOL scores below the 3 standard deviations of the mean SGOL scores of all ‘losses’ 
scores were sselected as significantly deleted genes. 
 
Sequence Validation  
For enrichment of the regions containing putative alterations, genomic coordinates of the 
putative WGS targets were used to order Nimbelgen Seqcap EZ solution bait sets 
(Roche). The library construction and target enrichment was performed per 
manufacturer’s instructions using repli-G (Qiagen) whole genome amplified DNA. 
Enriched targets were sequenced on the Illumina platform using paired end 100 cycle 
sequencing. The resulting data was converted to FASTQ files using CASAVA 1.8.2 
(Illumina) and mapped with BWA prior to pipeline analysis. 
 
Statistical Methods 
Kaplan-Meier method was used to estimate the overall survival and event-free survival 
curves. Log-rank test was performed to test the significant difference of survival curves 
between TP53 missense mutation group and the TP53 truncating mutation group in SAS 
version 9.2. 
We used the MuSiC software(Dees et al., 2012) to identify significantly mutated 
base-level mutation rate for SVs in each tumor under the null hypothesis that SV 
breakpoints were distributed randomly within the genome and the number of tumors 




 Telomere length was predicted in silico by counting the number of next-generation 
sequencing reads containing the telomeric-repeat sequence TTAGGG (Castle et al., 
2010). The resulting number of reads was normalized to the average genomic coverage, 
and the difference in diagnostic and germline telomeric sizes was calculated. Telomere 
length was validated in vitro in NBs expressing an ATRX aberration as described 
previously (Cawthon, 2002; O'Callaghan et al., 2008).  Briefly 15-20ng of diagnostic and 
germline WGA amplified DNA was subject to qPCR using two sets of primers in 
separate reactions, one to amplify telomeric sequence and one to amplify a common 
gene; 36B4 (RPLP0).  Ct values obtained were compared to those of two standard curves, 
a telomeric standard curve performed on known quantities of a telomeric 84mer and one 
using an oligomer of 36B4 (RPLP0).  All reactions were performed in triplicate with both 
tumor and germline DNA and both assays on the same plate.  All reactions were carried 
out using Brilliant III Ultra-Fast SYBR Green master mix (Agilent) on a Stratagene 
32
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Mx3000 thermal cycler using a melting temperature of 60oC.   This allowed us to 
determine the telomere length in Kb per diploid genome. The forward primer for 
telomere analysis was:  
5’- CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT-3’ 
The reverse primer for telomere analysis was: 
5’-GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCC-3’ 
The forward primer for the internal control 36B4 (RPL0) gene was: 
5’- CAGCAAGTGGGAAGGTGTAATCC-3’ 
The reverse primer for the internal control 36B4 (RPL0) gene was: 
5’- CCCATTCTATCATCAACGGGTACAA-3’ 
The standard used to generate the standard curve for telomeres was: 
5’-(TTAGGG)14-3’ 





ATRX Immunohistochemistry  
Formalin-fixed, paraffin-embedded tissues were cut into 4-µm-thick sections and 
immunostained with a polyclonal antibody against ATRX (1:600; Sigma-Aldrich) by 
using heat-induced epitope retrieval and Leica Polymer Refine Detection Kit (Leica 
Microsystems) on a Leica Bond system after 15-minute antibody incubation. 
 
Telomere FISH 
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Interphase FISH was performed on 4-µm-thick, formalin-fixed, paraffin-embedded tissue 
sections. The Cy3-labeled TelG probe (PNAbio) was co-denatured with the target cells 
on a hotplate at 90 °C for 12 minutes. The slides were incubated for 48 hours at 37 °C 
and then washed in 4 M Urea/2× SSC at 45 °C for 5 minutes. Nuclei were counterstained 
with DAPI (200 ng/mL) (Vector Labs). 
 
Tumor Purity Estimations 
For germline heterogeneous SNPs, loss of heterozygosity (LOH) measures the absolute 
difference between the mutant allele fraction in tumor and that in germline sample (0.5).  
LOH is the result of copy number alterations and/or copy neutral-LOH in tumor cells.  
Compared to copy number gains (a single copy gain in 100% tumor results in a LOH 
value of 0.167), regions with copy number loss showed stronger LOH (a single copy loss 
in 100% tumor result in a LOH value of 0.5). Consequently, we used LOH signals in 
copy neutral or heterozygous copy number loss regions (CNA value between [-1, 0]) to 
estimate tumor purity for all WGS samples.  Briefly, a single copy loss in	  𝑥%	  tumor cells 
resulted in an estimated CNA value of	  − !!""	  and a LOH value of	   !!""!!!.	  Assuming the 
remaining LOH signal came from CN-LOH (CN-LOH in	  𝑥%	  tumor cell resulted in a 
LOH value of	   !!""),	  the tumor content in a region could be estimated as the sum of the 
fraction with copy number loss and the fraction with CN-LOH by:	  −𝐶𝑁𝐴 + 2 ∗𝐿𝑂𝐻 − !!"#!!!!"# .	  	  Using tumor content estimates from various regions within the 
genome, we performed an unsupervised clustering analysis using the mclust package 
(version 3.4.8) in R (version 2.11.1).  The tumor purity of the sample was defined as the 
highest cluster center value among all clusters.  
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Purity Adjusted Mutant Allele Fraction (MAF) Estimation 
MAF for validated SNVs was estimated as #!"#$%!  !"#$%#!"#$%  !"#$% × !"#$%  !"#$%&  using deep 
sequencing data. The frequency of SV was determined by a process of re-mapping all 
reads at breakpoints to both SV and non-SV templates using a BWA Smith-Waterman 
based approach. To do this, we use the assembled consensus sequence from CREST 
result as SV template. From comparison, a pool of non-SV templates were constructed by 
including: 1, directly pull out the flanking sequences of 100 bp of each side of the 
breakpoint from reference genome (GRCh37-Lite); 2, assemble non-SV reads around the 
breakpoint from the bam file, where non-SV reads were defined by: any non-duplicate, 
non-softclipped, reads that contains at least 10 bases mapped on each side of a 
breakpoint, and requiring for at least one of two sides of that breakpoint, all bases are 
mapped in the read within a 10 bp continuous window immediately next to the 
breakpoint. We then extracted all reads at both SV break points, together with any 
unmapped or partially mapped (soft-clipped) reads within 4 kb of the breakpoints, and 
perform a pair-wise mapping and comparison for the SV and each of the non-SV 
templates to determine the status of individual read. Reads only covering the breakpoint 
in the SV template, but not in the non-SV template, are considered as SV supporting 
reads, and verse versa. If there are any reads covering breakpoint in both SV and normal 
template, we calculated a local alignment score within a 10-bp window of the breakpoint 
from SV and normal templates, and chose the template with higher score. In the end, the 
statuses of every read from all pair-wise comparisons were summarized to generate a 
consensus status. Any reads with conflicting statuses, i.e., called as SV in one run and 
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non-SV in another run will be considered as “unknown”. The SV mutant allele frequency 
was calculate by the ratio of number of SV reads to the total number of SV, non-SV, and 
unknown reads. 	  
Tumor Heterogeneity Estimation 
We used all validated autosomal SNVs satisfying the following criteria in heterogeneity 
analysis: 
1) In copy neutral region (Log2ration between (-0.1, 0.1) in CNV analysis). 
2) Not in regions with LOH (LOH value < 0.12 + min (0.08 purity*0.1). 
3) With MAF > 0.05 or mutant allele count > 2. 
We drew the kernel density estimate plot for MAFs of the qualifying SNVs using the 
density function in the stat package in R.  For samples with at least 50 qualifying SNVs, 
we also estimated the number of significant peaks and the relative MAF component for 
each peak (peaks with less than 5 SNVs, peaks with less than 1% SNVs, and peaks with 
excessive variance were ignored).  A sample with heterogeneity shows density peaks at a 
MAF smaller than 0.5 (the expected MAF assuming heterogeneous SNVs). 
 
Kataegis Analysis 
Kataegis analysis was performed on all validated Tier1-3 SNVs and SV breakpoints for 
each sample. The intermutation distance for a SNV was calculated as the distance to its 
nearest neighbor. For each SNV, its distance to the nearest validated SV breakpoint was 
also calculated. We defined microclusters of kataegis as clusters that contain at least 5 
consecutive SNVs with inter-variant distance less than 10 kb.  Mutant allele frequency 
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(MAF) was estimated for SNVs with at least 20X coverage in tumor BAMs based on 
deep sequencing of custom capture validation. 
We derived copy number of SNVs from the CONSERTING analysis.  For each 
SNV, the CNV segment covering the SNV was identified and the corresponding CN was 
estimated after tumor purity adjustment and rounded to the nearest integer. 
 
 
Statistical evaluation of chromothripsis in OS tumors analyzed by WGS 
 
Chromothripsis was described as localized chromosome shattering and repair occurs in a 
single event. The initial criterion is oscillation between restricted CNV states (Stephens et 
al. 2011(Stephens et al., 2011)), which were found in 4 OS tumors in this study. Most 
recently, Korbel and Campbell (Korbel and Campbell, 2013) proposed four potential 
criteria for assessing chromothripsis: 1) clustering of breakpoints; 2) randomness of DNA 
fragment joins; 3) randomness of DNA fragment order; and 4) ability to walk the 
derivative chromosome. Since randomness of DNA fragment order (Criterion 3) was not 
entirely valid even in Korbel and Campbell’s own analysis, we decided not to evaluate 
this feature. For the 4 tumors in Supplementary Table 5, we performed Bartlett's 
goodness-of-fit test for exponential distribution to assess whether the distribution of SV 
breakpoints in each tumor departs from the null hypothesis of random distribution. A 
significant departure from random distribution supports clustering of SV breakpoints. To 
evaluate whether there is any bias in the DNA fragment joints categorized by the SV 
types (i.e. deletion, tandem duplication, head-to-head re-arrangements and tail-to-tail re-
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arrangements), we applied goodness-of-fit test separately for inter- and intra- 
chromosomal events with a minimum of 5 SVs. A significant p value suggests biased 
fragment joins, which would not support chromothripsis. When both inter- and intra- 
chromosomal data are available, we reported the lower p value to represent a more 
conservative assessment of the random distribution for DNA fragment joints. 
The significant chromothripsis regions were chromosome 14 in SJOS002_D (p=2.09E-
09), chromosome 17 in SJOS003_D (p=9.65E-05), chromosome 6 in SJOS005_D 
(p=1.75E-90) and chromosome 13 in SJOS010_M (p=2.21E-35). 
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